Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C
Main Author: | |
---|---|
Publication Date: | 2020 |
Other Authors: | , , , |
Format: | Article |
Language: | por |
Source: | BEPA. Boletim epidemiológico paulista (Online) |
Download full: | https://periodicos.saude.sp.gov.br/BEPA182/article/view/33949 |
Summary: | Background: Recently, the management of patients chronically infected with the hepatitis C virus has progressed, including second generation direct-acting antivirals (DAA) that have potential to clear infection in most patients, especially genotype 1-infected patients. Objectives: Evaluate the sustained virologic response (SVR) of Hepatitis C treatment with second-generation DAAs made available by the Ministry of Health in follow-up patients of a São Paulo health service. Methods: This was a retrospective observational study, based on secondary data obtained from GAL and MEDEX systems. Briefly, 615 convenience samples were analyzed of patients who underwent second-generation DAAs treatment from June 2016 to April 2018. Demographic and clinical data were also analyzed. Results: SVR was observed in 600 treated patients (97.6%). Further, 98.4% and 94.7% of genotype 1 and genotype 3 patients, respectively, responded to treatment (P = 0.02). Among patients who did not respond to treatment, 93.3% were male, naive treatment and were treated for 12 weeks, except one genotype 1, HIV-coinfected patient who received treatment for 24 weeks. Conclusions: A high rate of SVR was found for Hepatitis C treatment with second-generation DAAs. SVR was significantly reduced in male and genotype 3-infected patients, although it still exceeded 90%. Further, HIV coinfection showed no association with reduced SVR rates (p=0.98). |
id |
SESSP_5a19f00829e0da3b52cab80e8e35014e |
---|---|
oai_identifier_str |
oai:ojs.periodicos.saude.sp.gov.br:article/33949 |
network_acronym_str |
SESSP |
network_name_str |
BEPA. Boletim epidemiológico paulista (Online) |
repository_id_str |
|
spelling |
Sustained virologic response to second-generation direct-acting antivirals for Hepatitis CResposta virológica sustentada às drogas de ação direta de segunda geração para hepatite CHepatite C crônicaEstudo observacionaTratamentoGenótipoResposta virológica sustentadaChronic Hepatitis CObservational studyTreatmentGenotypeSustained virologic responseBackground: Recently, the management of patients chronically infected with the hepatitis C virus has progressed, including second generation direct-acting antivirals (DAA) that have potential to clear infection in most patients, especially genotype 1-infected patients. Objectives: Evaluate the sustained virologic response (SVR) of Hepatitis C treatment with second-generation DAAs made available by the Ministry of Health in follow-up patients of a São Paulo health service. Methods: This was a retrospective observational study, based on secondary data obtained from GAL and MEDEX systems. Briefly, 615 convenience samples were analyzed of patients who underwent second-generation DAAs treatment from June 2016 to April 2018. Demographic and clinical data were also analyzed. Results: SVR was observed in 600 treated patients (97.6%). Further, 98.4% and 94.7% of genotype 1 and genotype 3 patients, respectively, responded to treatment (P = 0.02). Among patients who did not respond to treatment, 93.3% were male, naive treatment and were treated for 12 weeks, except one genotype 1, HIV-coinfected patient who received treatment for 24 weeks. Conclusions: A high rate of SVR was found for Hepatitis C treatment with second-generation DAAs. SVR was significantly reduced in male and genotype 3-infected patients, although it still exceeded 90%. Further, HIV coinfection showed no association with reduced SVR rates (p=0.98).Introdução: Recentemente, o manejo de pacientes infectados cronicamente pelo vírus da Hepatite C tem progredido, incluindo os antivirais de ação direta (DAAs) de segunda geração, que têm potencial de clarear a infecção em muitos pacientes, especialmente naqueles infectados pelo genótipo 1. Objetivo: Avaliar a resposta virológica sustentada (RVS) ao tratamento para Hepatite C com as drogas de ação direta (DAA) de segunda geração, disponibilizados pelo Ministério da Saúde em pacientes acompanhados por um serviço de saúde da cidade de São Paulo. Métodos: Estudo retrospectivo observacional, baseado em dados secundários obtidos dos sistemas GAL e MEDEX. Foram analisadas 615 amostras de conveniência de pacientes que realizaram tratamento com os DAA de segunda geração no período de junho de 2016 a abril de 2018. Os dados demográficos e clínicos também foram analisados. Resultados: RVS foi observada em 600 pacientes (97,6%). Além disso, 98,4% e 94,7% dos pacientes genótipo 1 e 3, respectivamente, responderam ao tratamento (P = 0.02). Dentre os pacientes que não responderam ao tratamento, 93,3% eram do sexo masculino, virgens de tratamento, e foram tratados por 12 semanas, exceto 1 paciente genótipo 1 e coinfectado com HIV que tratou por 24 semanas. Conclusão: A alta taxa de RVS foi observada para tratamento da Hepatite C com os DAA de segunda geração. A RVS foi significativamente reduzida em pacientes do sexo masculino e infectados pelo genótipo 3, apesar de ainda ser superior a 90%. A coinfecção com o HIV não demonstrou associação com a redução das taxas de RVS (p=0,98).Coordenadoria de Controle de Doenças - Secretaria de Estado da Saúde de São Paulo2020-04-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionAvaliado pelos paresapplication/pdfhttps://periodicos.saude.sp.gov.br/BEPA182/article/view/3394910.57148/bepa.2020.v.17.33949BEPA. Boletim Epidemiológico Paulista; Vol. 17 No. 196 (2020); 3-12BEPA. Boletim Epidemiológico Paulista; Vol. 17 Núm. 196 (2020); 3-12BEPA. Boletim Epidemiológico Paulista ; v. 17 n. 196 (2020); 3-121806-42721806-423Xreponame:BEPA. Boletim epidemiológico paulista (Online)instname:Secretaria de Estado da Saúde de São Paulo (SES-SP)instacron:SESSPporhttps://periodicos.saude.sp.gov.br/BEPA182/article/view/33949/32728Copyright (c) 2020 Adriana Parise Compri, Vanessa Cristina Martins Silva, Marcilio Figueiredo Lemos, Isabel Takano Oba, Regina Célia Moreirainfo:eu-repo/semantics/openAccessCompri, Adriana PariseSilva, Vanessa Cristina MartinsLemos, Marcilio FigueiredoOba, Isabel TakanoMoreira, Regina Célia2023-11-08T14:20:41Zoai:ojs.periodicos.saude.sp.gov.br:article/33949Revistahttps://periodicos.saude.sp.gov.br/BEPA182/indexPUBhttps://periodicos.saude.sp.gov.br/BEPA182/oaibepa@saude.sp.gov.br | periodicossp@saude.sp.gov.brhttps://doi.org/10.57148/bepa1806-42721806-423Xopendoar:2023-11-08T14:20:41BEPA. Boletim epidemiológico paulista (Online) - Secretaria de Estado da Saúde de São Paulo (SES-SP)false |
dc.title.none.fl_str_mv |
Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C Resposta virológica sustentada às drogas de ação direta de segunda geração para hepatite C |
title |
Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C |
spellingShingle |
Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C Compri, Adriana Parise Hepatite C crônica Estudo observaciona Tratamento Genótipo Resposta virológica sustentada Chronic Hepatitis C Observational study Treatment Genotype Sustained virologic response |
title_short |
Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C |
title_full |
Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C |
title_fullStr |
Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C |
title_full_unstemmed |
Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C |
title_sort |
Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C |
author |
Compri, Adriana Parise |
author_facet |
Compri, Adriana Parise Silva, Vanessa Cristina Martins Lemos, Marcilio Figueiredo Oba, Isabel Takano Moreira, Regina Célia |
author_role |
author |
author2 |
Silva, Vanessa Cristina Martins Lemos, Marcilio Figueiredo Oba, Isabel Takano Moreira, Regina Célia |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Compri, Adriana Parise Silva, Vanessa Cristina Martins Lemos, Marcilio Figueiredo Oba, Isabel Takano Moreira, Regina Célia |
dc.subject.por.fl_str_mv |
Hepatite C crônica Estudo observaciona Tratamento Genótipo Resposta virológica sustentada Chronic Hepatitis C Observational study Treatment Genotype Sustained virologic response |
topic |
Hepatite C crônica Estudo observaciona Tratamento Genótipo Resposta virológica sustentada Chronic Hepatitis C Observational study Treatment Genotype Sustained virologic response |
description |
Background: Recently, the management of patients chronically infected with the hepatitis C virus has progressed, including second generation direct-acting antivirals (DAA) that have potential to clear infection in most patients, especially genotype 1-infected patients. Objectives: Evaluate the sustained virologic response (SVR) of Hepatitis C treatment with second-generation DAAs made available by the Ministry of Health in follow-up patients of a São Paulo health service. Methods: This was a retrospective observational study, based on secondary data obtained from GAL and MEDEX systems. Briefly, 615 convenience samples were analyzed of patients who underwent second-generation DAAs treatment from June 2016 to April 2018. Demographic and clinical data were also analyzed. Results: SVR was observed in 600 treated patients (97.6%). Further, 98.4% and 94.7% of genotype 1 and genotype 3 patients, respectively, responded to treatment (P = 0.02). Among patients who did not respond to treatment, 93.3% were male, naive treatment and were treated for 12 weeks, except one genotype 1, HIV-coinfected patient who received treatment for 24 weeks. Conclusions: A high rate of SVR was found for Hepatitis C treatment with second-generation DAAs. SVR was significantly reduced in male and genotype 3-infected patients, although it still exceeded 90%. Further, HIV coinfection showed no association with reduced SVR rates (p=0.98). |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-04-30 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Avaliado pelos pares |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://periodicos.saude.sp.gov.br/BEPA182/article/view/33949 10.57148/bepa.2020.v.17.33949 |
url |
https://periodicos.saude.sp.gov.br/BEPA182/article/view/33949 |
identifier_str_mv |
10.57148/bepa.2020.v.17.33949 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://periodicos.saude.sp.gov.br/BEPA182/article/view/33949/32728 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Coordenadoria de Controle de Doenças - Secretaria de Estado da Saúde de São Paulo |
publisher.none.fl_str_mv |
Coordenadoria de Controle de Doenças - Secretaria de Estado da Saúde de São Paulo |
dc.source.none.fl_str_mv |
BEPA. Boletim Epidemiológico Paulista; Vol. 17 No. 196 (2020); 3-12 BEPA. Boletim Epidemiológico Paulista; Vol. 17 Núm. 196 (2020); 3-12 BEPA. Boletim Epidemiológico Paulista ; v. 17 n. 196 (2020); 3-12 1806-4272 1806-423X reponame:BEPA. Boletim epidemiológico paulista (Online) instname:Secretaria de Estado da Saúde de São Paulo (SES-SP) instacron:SESSP |
instname_str |
Secretaria de Estado da Saúde de São Paulo (SES-SP) |
instacron_str |
SESSP |
institution |
SESSP |
reponame_str |
BEPA. Boletim epidemiológico paulista (Online) |
collection |
BEPA. Boletim epidemiológico paulista (Online) |
repository.name.fl_str_mv |
BEPA. Boletim epidemiológico paulista (Online) - Secretaria de Estado da Saúde de São Paulo (SES-SP) |
repository.mail.fl_str_mv |
bepa@saude.sp.gov.br | periodicossp@saude.sp.gov.br |
_version_ |
1838465355713871872 |